Evidence map›Paper›PMID 37373354›Full record

SynthesisInternational journal of molecular sciences2023

Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.

Dani Ran Castillo, Daniel Park, Won Jin Jeon, Bowon Joung, Jae Lee, Chieh Yang, Bryan Pham, Christopher Hino, Esther Chong, Andrea Shields and 5 more

Open access · goldAbstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Dani Ran CastilloDepartment of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.ORCID 0000-0002-5762-6683
Daniel ParkDepartment of Internal Medicine, School of Medicine, University of California San Francisco-Fresno, Fresno, CA 93701, USA.
Won Jin JeonDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.ORCID 0000-0001-5212-5284
Bowon JoungDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
Jae LeeSchool of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
Chieh YangDepartment of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA 92521, USA.ORCID 0000-0003-2242-0447
Bryan PhamDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
Christopher HinoDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.ORCID 0000-0003-4637-4481
Esther ChongDepartment of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.ORCID 0000-0002-0508-9521
Andrea ShieldsDepartment of Pathology, Loma Linda University, Loma Linda, CA 92354, USA.
Anthony NguyenDepartment of Nutrition, Texas A&M University, College Station, TX 77030, USA.
Joel BrothersDepartment of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
Yan LiuDepartment of Pathology, Loma Linda University, Loma Linda, CA 92354, USA.
Ke K ZhangDepartment of Nutrition, Texas A&M University, College Station, TX 77030, USA.
Huynh CaoDepartment of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
Loma Linda University · USPrevention Institute · USTexas A&M University · USUniversity of California, Riverside · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6- MCL. 2. BCL6+/CD10+ vs. BCL6-/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan-Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months;

Indexed as

Lymphoma, Mantle-CellAdultHumansKi-67 AntigenNeprilysinPrognosisProto-Oncogene Proteins c-bcl-6Retrospective StudiesBCL6 protein, humanKi-67 AntigenNeprilysinProto-Oncogene Proteins c-bcl-6aberrant MCL immunophenotypeBCL6CD10overall survival

Identifiers

PMID37373354
PMCPMC10298847
OpenAlexW4380991878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.